These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 9707993)
1. [Utility of desmopressin in 4 cases of thrombocytopathies associated with giant platelets]. Martínez-Murillo C; Quintana-González S; Ambriz-Fernández R; Arzate-Hernández G; Gutiérrez-Romero M; Gaminio-Gómez E Rev Invest Clin; 1997; 49(4):281-6. PubMed ID: 9707993 [TBL] [Abstract][Full Text] [Related]
2. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235 [TBL] [Abstract][Full Text] [Related]
3. Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: correlation with the bleeding time. Cattaneo M; Pareti FI; Zighetti M; Lecchi A; Lombardi R; Mannucci PM J Lab Clin Med; 1995 Apr; 125(4):540-7. PubMed ID: 7706911 [TBL] [Abstract][Full Text] [Related]
4. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [TBL] [Abstract][Full Text] [Related]
5. Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome. Pfueller SL; Howard MA; White JG; Menon C; Berry EW Thromb Haemost; 1987 Dec; 58(4):1060-3. PubMed ID: 3502198 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial. Rao AK; Ghosh S; Sun L; Yang X; Disa J; Pickens P; Polansky M Thromb Haemost; 1995 Oct; 74(4):1071-8. PubMed ID: 8560416 [TBL] [Abstract][Full Text] [Related]
7. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction. Rose SS; Faiz A; Miller CH; Saidi P; Philipp CS Haemophilia; 2008 May; 14(3):571-8. PubMed ID: 18312366 [TBL] [Abstract][Full Text] [Related]
8. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders. Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449 [TBL] [Abstract][Full Text] [Related]
12. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Casonato A; Steffan A; Pontara E; Zucchetto A; Rossi C; De Marco L; Girolami A Thromb Haemost; 1999 Feb; 81(2):224-8. PubMed ID: 10063996 [TBL] [Abstract][Full Text] [Related]
13. [Shortening of acetylsalicylic acid-prolonged bleeding time by means of desmopressin]. Beck KH; Bleckmann U; Mohr P; Kretschmer V; Huss B Beitr Infusionsther Transfusionsmed; 1994; 32():437-9. PubMed ID: 9480140 [TBL] [Abstract][Full Text] [Related]
15. Desmopressin (DDAVP) for treatment of disorders of hemostasis. Mannucci PM Prog Hemost Thromb; 1986; 8():19-45. PubMed ID: 3104987 [TBL] [Abstract][Full Text] [Related]
16. [Von Willebrand disease: characteristics and response to desmopressin. Study of 103 cases]. César JM; Avello AG; Vecino A; Cerveró C; Laraña JG; Fuertes IF; Villarrubia J; López J; de Oteyza JP; Velasco JL; Cantalapiedra A; Herrera P; Herrero S; Navarro JL Med Clin (Barc); 1998 Nov; 111(16):601-3. PubMed ID: 9881332 [TBL] [Abstract][Full Text] [Related]
17. Bernard-Soulier syndrome in two Swedish families: effect of DDAVP on bleeding time. Waldenström E; Holmberg L; Axelsson U; Winqvist I; Nilsson IM Eur J Haematol; 1991 Mar; 46(3):182-7. PubMed ID: 1901273 [TBL] [Abstract][Full Text] [Related]
18. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium. Escolar G; Cases A; Monteagudo J; Garrido M; Lopez J; Ordinas A; Revert L; Castillo R J Lab Clin Med; 1989 Jul; 114(1):36-42. PubMed ID: 2738447 [TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo effects of desmopressin on platelet function. Balduini CL; Noris P; Belletti S; Spedini P; Gamba G Haematologica; 1999 Oct; 84(10):891-6. PubMed ID: 10509036 [TBL] [Abstract][Full Text] [Related]
20. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Cattaneo M; Tenconi PM; Alberca I; Garcia VV; Mannucci PM Thromb Haemost; 1990 Nov; 64(3):358-60. PubMed ID: 2096487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]